Status: Recruiting
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Prospective, multicenter, single arm, phase II study, to evaluate the efficacy of the combination rituximab-golcadomide as a chemo free approach in a population of older patients with new diagnosis of DLBCL, defined as frail according to a sGA evaluation and not candidate for the standard R-CHOP (or R-CHOP like) treatments.
Participants needed: 47
Trial details
Phase: Phase 2Age: 80+Biological sex: AllType: InterventionalSponsor: Fondazione Italiana Linfomi - ETSUpdated: Jan 2, 2026Locations: 20
Eligibility criteria
Able to provide written informed consent form approved by the National Ethics Co... [+17]
Histological diagnosis different from DLBCL [+10]